The present invention relates to the use of an inhibitor of an ENT family transporter for the treatment of cancer. The invention further relates to the combined use of such inhibitor of an ENT family transporter with an adenosine receptor antagonist, for the treatment of cancer. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination.

The present invention relates to the use of an inhibitor of an ENT family transporter for the treatment of cancer. The invention further relates to the combined use of such inhibitor of an ENT family transporter with an adenosine receptor antagonist, for the treatment of cancer. The invention further relates to a pharmaceutical composition and a kit of parts comprising such combination.

The present disclosure relates to a controlled release complex of a carboxylated polymer having carboxyl groups having a degree of substitution of about 0.1 to about 1.0, forming a complex through ionic interaction with an antimalarial alkaloid extract; a solid oral dosage form comprising the same, and a solid oral dosage form comprising an antimalarial drug combination which comprises the controlled release complex of the present invention and an antimalarial drug.

Disclosed herein are compositions and methods useful for the treatment of pulmonary hypertension, such as pulmonary arterial hypertension (PAH), in a subject in need thereof. Also disclosed herein are compositions and methods useful for the treatment of cancers characterized by an increase in HIT-2 a expression and/or activity in a subject in need thereof. In some embodiments, the methods include administering a therapeutic composition comprising one or more of ethacridine, propantheline, etoposide, irinotecan, quinidine, and hydroxy ethylapoquimne (HEAQ), and/or an analog thereof.

Disclosed herein are compositions and methods useful for the treatment of pulmonary hypertension, such as pulmonary arterial hypertension (PAH), in a subject in need thereof. Also disclosed herein are compositions and methods useful for the treatment of cancers characterized by an increase in HIT-2 a expression and/or activity in a subject in need thereof. In some embodiments, the methods include administering a therapeutic composition comprising one or more of ethacridine, propantheline, etoposide, irinotecan, quinidine, and hydroxy ethylapoquimne (HEAQ), and/or an analog thereof.

Compositions and methods for the treatment or prophylaxis of viral and other infections (e.g., coronavirus) are provided. The compositions typically comprise a quinoline derivative and an additional anti-viral agent. Incorporations of these agents into fabrics for use as filtration devices which forestall infection is also disclosed.

Compositions and methods for the treatment or prophylaxis of viral and other infections (e.g., coronavirus) are provided. The compositions typically comprise a quinoline derivative and an additional anti-viral agent. Incorporations of these agents into fabrics for use as filtration devices which forestall infection is also disclosed.

Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia.

Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia.

Disclosed herein are methods of treating a complication of a hemolysis and/or an inflammasome activation-associated disease comprising administering to a patient in need thereof quinine, or a derivative or salt thereof, or the combination of quinine and hemin. Also disclosed is a method of reducing alloimmunization in chronically transfused subjects, comprising administering to a patient in need thereof a therapeutically effective dose of quinine.